19731-01-2

Basic information

• Product Name: Benzoic acid, 3-cyano-, hydrazide (9CI)
• Synonyms: Benzoic acid, 3-cyano-, hydrazide (9CI);3-cyanobenzohydrazide(SALTDATA: FREE)
• CAS NO: 19731-01-2
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16068
• Product Categories: AMIDE
• Mol File: 19731-01-2.mol

Chemical Properties

• Appearance: /
• Density: 1.289g/cm³
• Refractive Index: 1.61
• Storage Temp.: 2-8°C
• PKA: 11.63±0.10(Predicted)
• CAS DataBase Reference: Benzoic acid, 3-cyano-, hydrazide (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-cyano-, hydrazide (9CI)(19731-01-2)
• EPA Substance Registry System: Benzoic acid, 3-cyano-, hydrazide (9CI)(19731-01-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 19731-01-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 3-cyano-, hydrazide (9CI) is used as a key intermediate in the synthesis of pharmaceutical compounds. Its ability to act as an antifungal and antibacterial agent makes it a promising candidate for the development of new drugs targeting various infections and diseases.
Used in Agricultural Industry:
In agriculture, Benzoic acid, 3-cyano-, hydrazide (9CI) is utilized as a building block for the production of various agricultural products. Its antifungal and antibacterial properties contribute to the development of effective solutions for crop protection and enhancement of agricultural yields.
Used in Dye Production:
Benzoic acid, 3-cyano-, hydrazide (9CI) is employed as a building block in the production of dyes. Its chemical properties allow for the creation of a wide range of dyes with diverse color characteristics, catering to various applications in industries such as textiles, plastics, and printing.
Used in Rubber Chemicals Production:
This versatile chemical compound is also used in the production of rubber chemicals. Benzoic acid, 3-cyano-, hydrazide (9CI) contributes to the development of rubber additives and modifiers that improve the performance and durability of rubber products in various applications, including automotive, industrial, and consumer goods.

InChI:InChI=1/C8H7N3O/c9-5-6-2-1-3-7(4-6)8(12)11-10/h1-4H,10H2,(H,11,12)

Upstream product

• 2463-16-3 ethyl 3-cyanobenzoate 
• 1711-11-1 3-cyanobenzoyl chloride 
• 1877-72-1 3-Cyanobenzoic acid 
• 13531-48-1 methyl 3-cyanobenzoate 

Downstream Products

• 4291-06-9 3-(5-phenyl-[1,3,4]thiadiazol-2-yl)-benzonitrile 
• 161013-24-7 C₉H₅N₃OS 
• 1456613-80-1 3-(7-oxo-5-thioxo-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)benzonitrile 
• 1456614-08-6 C₁₃H₁₂N₆O₂S 
• 1016517-38-6 3-(5-amino-1H-1,2,4-triazol-3-yl)benzonitrile 

Relevant articles and documents

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS

The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer

Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents

Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of Mycobacterium tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed. An attractive target for the development of new antitubercular agents is the salicylate synthase MbtI, an essential enzyme for the mycobacterial siderophore biochemical machinery, absent in human cells. A set of analogues of I and II, two of the most potent MbtI inhibitors identified to date, was synthesized, characterized, and tested to elucidate the structural requirements for achieving an efficient MbtI inhibition and a potent antitubercular activity with this class of compounds. The structure-activity relationships (SAR) here discussed evidenced the importance of the furan as part of the pharmacophore and led to the preparation of six new compounds (IV-IX), which gave us the opportunity to examine a hitherto unexplored position of the phenyl ring. Among them emerged 5-(3-cyano-5-(trifluoromethyl)phenyl)furan-2-carboxylic acid (IV), endowed with comparable inhibitory properties to the previous leads, but a better antitubercular activity, which is a key issue in MbtI inhibitor research. Therefore, compound IV offers promising prospects for future studies on the development of novel agents against mycobacterial infections.

A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition

Glycogen synthase kinase 3β (GSK-3β) and casein kinase 1δ (CK-1δ) are emerging targets for the treatment of neuroinflammatory disorders, including Parkinson's disease. An inhibitor able to target these two kinases was developed by docking-based design. Compound 12, 3-(7-amino-5-(cyclohexylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)-2-cyanoacrylamide, showed combined inhibitory activity against GSK-3β and CK-1δ [IC50(GSK-3β)=0.17 μm; IC50(CK-1δ)=0.68 μm]. In particular, classical ATP competition was observed against CK-1δ, and a co-crystal of compound 12 inside GSK-3β confirmed a covalent interaction between the cyanoacrylamide warhead and Cys199, which could help in the development of more potent covalent inhibitors of GSK-3β. Preliminary studies on in vitro models of Parkinson's disease revealed that compound 12 is not cytotoxic and shows neuroprotective activity. These results encourage further investigations to validate GSK-3β/CK-1δ inhibition as a possible new strategy to treat neuroinflammatory/degenerative diseases.

Novel Compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.

Synthesis and evaluation of novel azoles as potent antifungal agents

Using a rational approach to the design of antifungal agents, a series of azole agents with 1,3,4-oxadiazole side chains were designed and synthesized. The results of preliminary in vitro antifungal tests with eight human pathogenic compounds showed that all of the title compounds exhibited excellent activities against all of the tested fungi except Aspergillus fumigatus. Compounds 11e and 11f were found to be the most effective, with a minimum inhibitory concentration of 0.0039 μg/mL, followed by voriconazole, which has a MIC of 0.0625 μg/mL. The 1,3,4-oxadiazole side chain is not the major contributor but plays a role in eliciting the observed antifungal activity.

OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

This invention relates to oxadiazolyl and thiadiazolyl derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

NEW COMPOUNDS

The present invention relates to new compounds of formula I, (I) a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.